An Emerging Leader in Cancer Diagnostics

Cancer Genetics, Inc. (CGI) is a leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.

Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our clinical reference laboratory is both CLIA-certified and CAP-accredited. In addition we have approvals and accreditations from the states of Florida, Maryland, New York, California, and New Jersey. Our clinical trial support services and global facilities help biotech and biopharma companies deliver more personalized treatments to market.

CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. Our dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests. CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.


Our History

Cancer Genetics, Inc. was founded by world-renowned cytogeneticist Dr. R.S.K. Chaganti. Today, CGI’s scientific advisory board includes key thought leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. Built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, the company continues to develop strong research collaborations with major cancer centers and academic institutions.

In 2013, CGI launched a joint-venture with Mayo Clinic, Oncospire Genomics. Working to meet areas of critical need in oncology, Oncospire Genomics seeks to improve cancer care by discovering and commercializing diagnostic tests that leverage NGS technology.

In 2014, CGI acquired Gentris, LLC (based in Raleigh, NC) and Bioserve Biotechnologis Pvt. Ltd. (based in Hyderabad, India. Gentris | A CGI Company is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. Gentris advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care. Gentris’ clinical trials services, as well as their international services and Shanghai, China operations, have been integrated into CGI’s Select One® clinical trials offering, allowing CGI to provide the most robust and personalized clinical trial services available to our biotech and pharma customers.


Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Reports
Click here to login and view your reports.